AUTHOR=Luo Shanxia , Guo Qiong , Yang Liu , Cheng Yifan , Long Youlin , Wang Xinyi , Liu Liqin , Yang Zixin , Hu Tengyue , Du Liang , Chen Min , Liao Ga 

TITLE=Characteristic and Early Discontinuation of Obsessive-Compulsive Disorder Trials Registered on ClinicalTrials.gov

JOURNAL=Frontiers in Psychiatry

VOLUME=Volume 12 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.650057

DOI=10.3389/fpsyt.2021.650057

ISSN=1664-0640

ABSTRACT=Objective
To analyze the characteristics and reasons of early discontinuation of Obsessive-compulsive disorder (OCD) trials registered on ClinicalTrials.gov.
Methods
We searched ClinicalTrials.gov for identifying the OCD trials, and related publications were searched by PubMed. The characteristics and confirmed whether a trial was timely published for further survival analysis were recorded. Cox regression were used to explore factors associated with early discontinuation in OCD trials.
Results
We included 298 therapy OCD trials. Most recruited less than 100 patients and were more likely to be conducted in adults. Two-third OCD studies were randomized, and 61.4% blinded OCD trials were single-blind or double-blind. Universities and hospitals were recorded as two primary sponsors in majority of OCD trials. 155 trials (52%) were completed, only 29% of them were published. Of those published trials, more than 70% had taken over one year to publish since completed. Behavioral therapy trials were of major treatment-aimed OCD trials, followed by drug trials (35.1%) and device/procedure trials (24.7%). Univariate Cox regression Indicated that involving drugs (HR=2.56, 95%CI 1.21-5.43), without collaborators (HR=3.87, 95%CI 1.62-9.26) and sponsored by industry (HR=3.97, 95%CI 1.49-10.53) are risk factor of early discontinuation in OCD trials. Further multivariate Cox regression showed that drug trials (HR=3.93, 95%CI 1.71-9.08) and without collaborators (HR=5.17, 95%CI 1.97-13.54) were independent risk factors of early trial discontinuation in OCD trials.
Conclusion
Diagnosis and prevention of OCD are rarely concerned in trials. Underreporting and delayed reporting remains problems. Both intervention type and participation of collaborators are associated with early discontinuation in OCD trials.